2015
Etiology of angiogenesis inhibition-related hypertension
Publication
Publication
Current Opinion in Pharmacology , Volume 21 p. 7- 13
Angiogenesis inhibition, targeting vascular endothelial growth factor (VEGF) or its receptors, is an established treatment for solid tumors. A common side effect of this treatment is the development of sometimes severe hypertension. This hypertension is associated with a decrease in nitric oxide production, activation of the endothelin-signaling pathway and renin suppression. The mechanism underlying activation of the endothelin-signaling pathway is not fully understood. Both activation of endothelial cells and disinhibition of the VEGF-induced suppression of endothelin production by endothelial cells may be involved. The development of hypertension can be a reason to discontinue the angiogenesis inhibitor, thereby compromising anticancer treatment, but possibly is also a biomarker for a favorable antitumor response.
Additional Metadata | |
---|---|
doi.org/10.1016/j.coph.2014.11.010, hdl.handle.net/1765/81731 | |
Current Opinion in Pharmacology | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
Lankhorst, S., Saleh, L., Danser, J., & van den Meiracker, A. (2015). Etiology of angiogenesis inhibition-related hypertension. Current Opinion in Pharmacology (Vol. 21, pp. 7–13). doi:10.1016/j.coph.2014.11.010 |